Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.897895
Keywords
RNA modifications; N6-methyladenosine; female malignancies; molecular mechanisms; immunotherapy
Categories
Funding
- National Natural Science Foundation of China [81802103, 81803938]
- Project of High-Level Talents in AHUTCM [2019rcZD001]
- Excellent Young Scholars Project of Natural Science Foundation of Anhui Province in China [2108085Y29]
- Natural Science Research Project of Colleges and Universities in Anhui Province [KJ2021A0557]
- Opening Project of Zhejiang Provincial Preponderant and Characteristic Subject of Key University (Chinese Traditional Medicine)
- Zhejiang Chinese Medical University [ZYXZD2019004]
Ask authors/readers for more resources
This review focuses on the mutual regulation of m(6)A and coding and non-coding RNAs, introducing the molecular mechanism of m(6)A methylation involved in regulation and its role in cancer treatment using common female malignant tumors as an example.
N-6-methyladenosine (m(6)A) is a major internal epigenetic modification in eukaryotic mRNA, which is dynamic and reversible. m(6)A is regulated by methylases (writers) and demethylases (erasers) and is recognized and processed by m(6)A-binding proteins (readers), which further regulate RNA transport, localization, translation, and degradation. It plays a role in promoting or suppressing tumors and has the potential to become a therapeutic target for malignant tumors. In this review, we focus on the mutual regulation of m(6)A and coding and non-coding RNAs and introduce the molecular mechanism of m(6)A methylation involved in regulation and its role in cancer treatment by taking common female malignant tumors as an example.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
